Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

Roberto Guariglia, Maria Carmen Martorelli, Oreste Villani, Giuseppe Pietrantuono, Giovanna Mansueto, Fiorella D'Auria, Vitina Grieco, Gabriella Bianchino, Rosa Lerose, Giovanni Battista Bochicchio, Pellegrino Musto

Research output: Contribution to journalArticlepeer-review

Abstract

Iron overload is a frequent consequence in transfusion-dependent myelodysplastic syndromes (MDSs), which often requires iron chelation therapy (ICT). Interestingly, ICT may sometimes induce a hematologic improvement that leads to significant reduction or complete interruption of blood transfusions. This phenomenon has been recently described in MDS treated with the new oral chelator deferasirox.Here we briefly review the literature about this phenomenon and discuss the possible biological mechanisms underlying hematologic effects of deferasirox in MDS, starting from a new paradigmatic case in whom both hemoglobin level and platelet count improved, inducing transfusion-independence, soon after starting the treatment with deferasirox.

Original languageEnglish
Pages (from-to)566-570
Number of pages5
JournalLeukemia Research
Volume35
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • Deferasirox
  • Hemopoietic improvement
  • Iron chelation
  • Myelodysplastic syndromes
  • Transfusion dependence

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review'. Together they form a unique fingerprint.

Cite this